MedTrace Logo

Treatment With Crizotinib Single Patient Expanded Access IND 134375

NCT03085186 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-08-29

No results posted yet for this study

Summary

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.

Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Conditions

  • Inflammatory Myofibroblastic Tumour

Interventions

DRUG

Crizotinib

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Jean M. Tersak, M.D.

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
2 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085186 on ClinicalTrials.gov